Breast Cancer

Excellent Responses to Atezolizumab in Small Subset of Women with Triple-Negative Breast Cancer

Phoebe Starr

May 2017, Vol 7, No 5 - AACR 2017 Highlights, Breast Cancer

Washington, DC—Preliminary data show excellent and durable responses to atezolizumab (Tecentriq) in 10% of women with triple-negative breast cancer, one of the most aggressive and difficult-to-treat cancers. Of the responders to atezolizumab, 100% were alive at 1 year compared with only 38% of nonresponders. The trick will be to identify which women will respond to immune checkpoint inhibitor therapy. Thus far, no biomarkers for response have been identified. [ Read More ]

Abemaciclib, a CDK4/CDK6 Inhibitor, Shows Promise in Early-Stage Breast Cancer

Phoebe Starr

March 2017, Vol 7, No 3 - Breast Cancer

Neoadjuvant therapy with the investigational CDK4/CDK6 inhibitor, abemaciclib, alone or in combination with anastrozole (Arimidex) showed promising activity in postmenopausal hormone receptor (HR)-positive, HER2-negative breast cancer enrolled in the phase 2 NeoMONARCH study. Correlative tissue studies demonstrated that abemaciclib inhibited cell-cycle proliferation and activated the immune system, supporting its anticancer activity. [ Read More ]

Benefit of Extended Adjuvant Aromatase Inhibition in Breast Cancer Questionable

Phoebe Starr

March 2017, Vol 7, No 3 - Breast Cancer

Extended adjuvant endocrine therapy beyond 5 years with an aromatase inhibitor (AI) failed to improve disease-free survival (DFS) in patients with hormone receptor (HR)-positive breast cancer who were enrolled in the 3 large National Surgical Adjuvant Breast and Bowel Project (NSABP) B-52, IDEAL, and DATA studies, which were presented at the 2016 San Antonio Breast Cancer Symposium. [ Read More ]